The DOI matches its Crossref record.
Results of a Phase II Study of the Antidepressant Effect of Rolipram
Abstract
The antidepressant effect of rolipram, believed to be based on a new mechanism of action, was investigated in an open phase II study in 10 depressive patients, most of whom had been refractory to previous antidepressant therapy. Five patients displayed a good to very good improvement of their depressive condition. Four patients failed to show any substantial improvement, and therapy had to be withdrawn in one case due to deterioration of the condition. In most cases, the antidepressant effect of the trial preparation became noticeable after 2-4 days of treatment only. Basing on the presented cases, the tolerance can be described as excellent compared to other antidepressants. Although, on the whole the trial yielded very encouraging results, only double-blind trials can determine the true antidepressant efficacy of rolipram. Zusammenfassung Die antidepressive Wirkung von Rolipram, die auf einen neuen Wirkungsmechanismus zurückgeführt wird, wurde in einer offenen Studie (Phase II) an 10 depressiven Patienten untersucht, von denen die meisten auf eine früher durchgeführte Behandlung mit Antidepressiva nicht angesprochen hatten. Fünf Patienten zeigten gute bis sehr gute Besserung ihres depressiven Zustands. Bei 4 Patienten blieb eine Besserung aus, in einem Fall mußte die Behandlung wegen der Verschlechterung des Zustands abgebrochen werden. In den meisten Fällen machte sich die antidepressive Wirkung des Versuchspräparates bereits nach 2-4tägiger Behandlungsdauer bemerkbar. Aufgrund der hier geschilderten Fälle muß die Verträglichkeit des Präparates, verglichen mit der anderer Antidepressiva, als ausgezeichnet angesehen werden. Obwohl im großen und ganzen gesehen die Studie durchaus ermutigende Ergebnisse erbrachte, kann die wirkliche antidepressive Wirksamkeit von Rolipram nur mit Hilfe von Doppelblindstudien ermittelt werden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Keynote review: Phosphodiesterase-4 as a therapeutic target
Houslay, M. D., Schafer, P., & Zhang, K. Y. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03622-6 · Cited by 635
Critical Role of Brain-Derived Neurotrophic Factor in Mood Disorders
Hashimoto, K., Shimizu, E., & Iyo, M. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.02.003 · Cited by 522
Manji, H. K., Quiroz, J. A., Sporn, J., Payne, J. L., Denicoff, K., A. Gray, N., Zarate, C. A., & Charney, D. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00117-3 · Cited by 505
Phosphodiesterases in the CNS: targets for drug development
Menniti, F. S., Faraci, W. S., & Schmidt, C. J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2058 · Cited by 391
Clinical and Molecular Genetics of the Phosphodiesterases (PDEs)
Azevedo, M. F., Faucz, F. R., Bimpaki, E., Horvath, A., Levy, I., de Alexandre, R. B., Ahmad, F., Manganiello, V., & Stratakis, C. A. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1053 · Cited by 325
Metadata
- Authors
- Zeller, E., Stief, H., Pflug, B., & Sastre-y-Hernández, M.
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 1984-11
- Volume
- 17
- Issue
- 06
- Pages
- 188-190
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W2009772232
- Cited by
- 179
- References
- 0
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results of a Phase II Study of the Antidepressant Effect of Rolipram. https://app.cochat.ai/papers/10.1055/s-2007-1017435
- The paper
- Zeller, E., Stief, H., Pflug, B., & Sastre-y-Hernández, M. (1984). Results of a Phase II Study of the Antidepressant Effect of Rolipram. Pharmacopsychiatry. https://doi.org/10.1055/s-2007-1017435
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.